{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:45:56Z","timestamp":1794242756789,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67528-4","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:25:47Z","timestamp":1766067947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1013-147X","authenticated-orcid":false,"given":"Jing","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0043-6073","authenticated-orcid":false,"given":"Yongqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9019-765X","authenticated-orcid":false,"given":"Dongen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-7721","authenticated-orcid":false,"given":"Bicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-9559","authenticated-orcid":false,"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-3508","authenticated-orcid":false,"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-3393","authenticated-orcid":false,"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7323-0331","authenticated-orcid":false,"given":"Jun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"67528_CR1","doi-asserted-by":"crossref","unstructured":"Ezequiel, M. et al. Hepatocellular carcinoma: Epidemiology, diagnosis and treatment. JHEP Rep. 7, 101571 (2025).","DOI":"10.1016\/j.jhepr.2025.101571"},{"key":"67528_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"67528_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"67528_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"67528_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 9, 1651\u20131659 (2023).","journal-title":"JAMA Oncol."},{"key":"67528_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med"},{"key":"67528_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"67528_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402, 1133\u20131146 (2023).","journal-title":"Lancet"},{"key":"67528_CR9","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau, T. et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.  Lancet 405, 1851\u20131864 (2025).","journal-title":"Lancet"},{"key":"67528_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","volume":"8","author":"M Pinter","year":"2023","unstructured":"Pinter, M., Scheiner, B. & Pinato, D. J. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol. Hepatol. 8, 760\u2013770 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"67528_CR11","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.jhepr.2022.100620","volume":"5","author":"B Scheiner","year":"2023","unstructured":"Scheiner, B. et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep. 5, 100620 (2023).","journal-title":"JHEP Rep."},{"key":"67528_CR12","doi-asserted-by":"publisher","unstructured":"Wong, J. S. L. et al. Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2020-001945 (2021).","DOI":"10.1136\/jitc-2020-001945"},{"key":"67528_CR13","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1007\/s00432-022-04206-8","volume":"149","author":"D Roessler","year":"2023","unstructured":"Roessler, D. et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. J. Cancer Res Clin. Oncol. 149, 3065\u20133073 (2023).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"67528_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"67528_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.01.001","volume":"111","author":"M Wahid","year":"2017","unstructured":"Wahid, M. et al. Pembrolizumab\u2019s non-cross resistance mechanism of action successfully overthrown ipilimumab. Crit. Rev. Oncol. Hematol. 111, 1\u20136 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"67528_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133.e1117 (2017).","journal-title":"Cell"},{"key":"67528_CR17","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","volume":"29","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus. Clin. Cancer Res. 29, 4088\u20134097 (2023).","journal-title":"Clin. Cancer Res."},{"key":"67528_CR18","doi-asserted-by":"publisher","first-page":"LBA432","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA432","volume":"42","author":"R Lencioni","year":"2024","unstructured":"Lencioni, R. et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J. Clin. Oncol. 42, LBA432 (2024).","journal-title":"J. Clin. Oncol."},{"key":"67528_CR19","first-page":"171","volume":"2","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences. J. Natl. Cancer Cent. 2, 171\u2013182 (2022).","journal-title":"J. Natl. Cancer Cent."},{"key":"67528_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","volume":"74","author":"TH Kim","year":"2021","unstructured":"Kim, T. H. et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. J. Hepatol. 74, 603\u2013612 (2021).","journal-title":"J. Hepatol."},{"key":"67528_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","volume":"141","author":"M Scorsetti","year":"2015","unstructured":"Scorsetti, M. et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J. Cancer Res. Clin. Oncol. 141, 1301\u20131309 (2015).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"67528_CR22","doi-asserted-by":"publisher","first-page":"568759","DOI":"10.3389\/fimmu.2020.568759","volume":"11","author":"YH Lee","year":"2020","unstructured":"Lee, Y. H., Tai, D., Yip, C., Choo, S. P. & Chew, V. Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond. Front. Immunol. 11, 568759 (2020).","journal-title":"Front. Immunol."},{"key":"67528_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06211-2","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis. 14, 679 (2023).","journal-title":"Cell Death Dis."},{"key":"67528_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo, S. et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct. Target. Ther. 8, 205 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"67528_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.  J. Exp. Med. 203, 1259\u20131271 (2006).","journal-title":"J. Exp. Med."},{"key":"67528_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0360-3016(03)00523-6","volume":"57","author":"M Moll\u00e0","year":"2003","unstructured":"Moll\u00e0, M. et al. Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int. J. Radiat. Oncol. Biol. Phys. 57, 264\u2013273 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"67528_CR27","doi-asserted-by":"publisher","unstructured":"Huang, J. et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat. Cancer. https:\/\/doi.org\/10.1038\/s43018-025-01018-w (2025).","DOI":"10.1038\/s43018-025-01018-w"},{"key":"67528_CR28","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","volume":"23","author":"SJ Dovedi","year":"2017","unstructured":"Dovedi, S. J. et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin. Cancer Res. 23, 5514\u20135526 (2017).","journal-title":"Clin. Cancer Res."},{"key":"67528_CR29","doi-asserted-by":"publisher","first-page":"104191","DOI":"10.1016\/j.critrevonc.2023.104191","volume":"192","author":"C Podesta","year":"2023","unstructured":"Podesta, C., Kayani, M., Goody, R. & Samson, A. Combination treatment of HCC with SBRT and immune checkpoint inhibition. Crit. Rev. Oncol. Hematol. 192, 104191 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"67528_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nm1730","volume":"14","author":"S Kashiwagi","year":"2008","unstructured":"Kashiwagi, S. et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 14, 255\u2013257 (2008).","journal-title":"Nat. Med."},{"key":"67528_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ijrobp.2024.09.024","volume":"121","author":"H Sheng","year":"2025","unstructured":"Sheng, H. et al. Antiangiogenic treatment facilitates the abscopal effect of radiation therapy combined with anti-PD-1 in hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 121, 534\u2013546 (2025).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"67528_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 293\u2013313 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"67528_CR33","doi-asserted-by":"publisher","first-page":"175883592513345","DOI":"10.1177\/17588359251334538","volume":"17","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Efficacy and safety of radiotherapy to delay second-line systemic therapy in patients with oligoprogressive hepatocellular carcinoma: study protocol of a multicentre, single-arm, phase II trial. Ther. Adv. Med Oncol. 17, 17588359251334538 (2025).","journal-title":"Ther. Adv. Med Oncol."},{"key":"67528_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47420-3","volume":"15","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nat. Commun. 15, 3260 (2024).","journal-title":"Nat. Commun."},{"key":"67528_CR35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study. Signal Transduct. Target Ther. 9, 280 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"67528_CR36","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2024.42.16_suppl.4007","volume":"42","author":"AB El-Khoueiry","year":"2024","unstructured":"El-Khoueiry, A. B. et al. International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). J. Clin. Oncol. 42, 4007 (2024).","journal-title":"J. Clin. Oncol."},{"key":"67528_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s44355-025-00018-y","volume":"2","author":"R Desert","year":"2025","unstructured":"Desert, R. et al. Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models. npj Gut Liver 2, 8 (2025).","journal-title":"npj Gut Liver"},{"key":"67528_CR38","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"67528_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay, C., Tanaka, A. & Sakaguchi, S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41, 450\u2013465 (2023).","journal-title":"Cancer Cell"},{"key":"67528_CR40","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada, T. et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA 116, 9999\u201310008 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67528_CR41","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68, 1653\u20131666 (2019).","journal-title":"Gut"},{"key":"67528_CR42","doi-asserted-by":"publisher","first-page":"958720","DOI":"10.3389\/fonc.2022.958720","volume":"12","author":"Q Xie","year":"2022","unstructured":"Xie, Q., Zhang, P., Wang, Y., Mei, W. & Zeng, C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: challenges and opportunities. Front. Oncol. 12, 958720 (2022).","journal-title":"Front. Oncol."},{"key":"67528_CR43","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10238-022-00972-4","volume":"23","author":"H Li","year":"2023","unstructured":"Li, H. et al. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin. Exp. Med. 23, 1537\u20131549 (2023).","journal-title":"Clin. Exp. Med."},{"key":"67528_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"67528_CR45","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan, A. et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J. Biol. Sci. 17, 3837\u20133849 (2021).","journal-title":"Int J. Biol. Sci."},{"key":"67528_CR46","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med 380, 1450\u20131462 (2019).","journal-title":"N. Engl. J. Med"},{"key":"67528_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi, M. et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal. Transduct. Target Ther. 9, 176 (2024).","journal-title":"Signal. Transduct. Target Ther."},{"key":"67528_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.radonc.2016.07.013","volume":"120","author":"I Popp","year":"2016","unstructured":"Popp, I., Grosu, A. L., Niedermann, G. & Duda, D. G. Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications. Radiother. Oncol. 120, 185\u2013194 (2016).","journal-title":"Radiother. Oncol."},{"key":"67528_CR49","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.celrep.2019.08.095","volume":"29","author":"BN Mills","year":"2019","unstructured":"Mills, B. N. et al. Stereotactic body radiation and interleukin-12 combination therapy eradicates pancreatic tumors by repolarizing the immune microenvironment. Cell Rep. 29, 406\u2013421.e405 (2019).","journal-title":"Cell Rep."},{"key":"67528_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62523-z","volume":"14","author":"YD Lin","year":"2024","unstructured":"Lin, Y. D. et al. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial. Sci. Rep. 14, 11486 (2024).","journal-title":"Sci. Rep."},{"key":"67528_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","volume":"180","author":"IM Chen","year":"2023","unstructured":"Chen, I. M. et al. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Eur. J. Cancer 180, 125\u2013133 (2023).","journal-title":"Eur. J. Cancer"},{"key":"67528_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002460","volume":"9","author":"E Beyranvand Nejad","year":"2021","unstructured":"Beyranvand Nejad, E. et al. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. J. Immunother. Cancer 9, e002460 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"67528_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41423-024-01238-7","volume":"22","author":"M Perez-Penco","year":"2025","unstructured":"Perez-Penco, M. et al. The antitumor activity of TGF\u03b2-specific T cells is dependent on IL-6 signaling. Cell. Mol. Immunol. 22, 111\u2013126 (2025).","journal-title":"Cell. Mol. Immunol."},{"key":"67528_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","volume":"26","author":"DT Fisher","year":"2014","unstructured":"Fisher, D. T., Appenheimer, M. M. & Evans, S. S. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 26, 38\u201347 (2014).","journal-title":"Semin Immunol."},{"key":"67528_CR55","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","volume":"76","author":"B Scheiner","year":"2022","unstructured":"Scheiner, B. et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J. Hepatol. 76, 353\u2013363 (2022).","journal-title":"J. Hepatol."},{"key":"67528_CR56","doi-asserted-by":"publisher","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01868-2 (2022).","DOI":"10.1038\/s41591-022-01868-2"},{"key":"67528_CR57","doi-asserted-by":"publisher","unstructured":"Wang, J. H. et al. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14020343 (2022).","DOI":"10.3390\/cancers14020343"},{"key":"67528_CR58","doi-asserted-by":"publisher","unstructured":"Wu, Y. L. et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14235834 (2022).","DOI":"10.3390\/cancers14235834"},{"key":"67528_CR59","doi-asserted-by":"publisher","first-page":"e077903","DOI":"10.1136\/bmjopen-2023-077903","volume":"14","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial. BMJ open 14, e077903 (2024).","journal-title":"BMJ open"},{"key":"67528_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride, S. et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J. Clin. Oncol. 39, 30\u201337 (2021).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67528-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:11:44Z","timestamp":1769213504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67528-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67528"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67528-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Y.Q. and G.M.H. declare employment with Nanjing Simcere Medical Laboratory Science Co., Ltd. The remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"823"}}